Chimeric immunomodulatory compounds and methods of using the same
First Claim
Patent Images
1. A method of modulating an immune response in an individual comprising administering to an individual a linear chimeric immunomodulatory compound (CIC) in an amount sufficient to modulate an immune response in said individual, wherein the linear CIC comprises a structure N1—
- S1—
N2—
S2—
N3,wherein N1, N2, and N3 are independently selected nucleic acid moieties comprising 3 to 7 bases, at least one of N1, N2, and N3 has the sequence 5′
-[(X)0-2]TCG[(X)2-4]-3′
, wherein each X is an independently selected nucleotide;
wherein S1 is a non-nucleic acid spacer moiety covalently bound to N1 and N2;
S2 is a non-nucleic acid spacer moiety covalently bound to N2 and N3;
S1 and S2 are the same or different;
each of S1 and S2 comprises hexaethylene glycol (HEG), triethyleneglycol (TEG), propyl, butyl, or hexyl; and
wherein said CIC has at least one immunomodulatory activity selected from the group consisting of (i) the ability to stimulate interferon-gamma (IFN-γ
) production by human peripheral blood mononuclear cells and (ii) the ability to stimulate interferon-alpha (IFN-α
) production by human peripheral blood mononuclear cells.
4 Assignments
0 Petitions
Accused Products
Abstract
The invention provides immunomodulatory compounds and methods for immunomodulation of individuals using the immunomodulatory compounds.
-
Citations
6 Claims
-
1. A method of modulating an immune response in an individual comprising administering to an individual a linear chimeric immunomodulatory compound (CIC) in an amount sufficient to modulate an immune response in said individual, wherein the linear CIC comprises a structure N1—
- S1—
N2—
S2—
N3,wherein N1, N2, and N3 are independently selected nucleic acid moieties comprising 3 to 7 bases, at least one of N1, N2, and N3 has the sequence 5′
-[(X)0-2]TCG[(X)2-4]-3′
, wherein each X is an independently selected nucleotide;wherein S1 is a non-nucleic acid spacer moiety covalently bound to N1 and N2;
S2 is a non-nucleic acid spacer moiety covalently bound to N2 and N3;
S1 and S2 are the same or different;
each of S1 and S2 comprises hexaethylene glycol (HEG), triethyleneglycol (TEG), propyl, butyl, or hexyl; andwherein said CIC has at least one immunomodulatory activity selected from the group consisting of (i) the ability to stimulate interferon-gamma (IFN-γ
) production by human peripheral blood mononuclear cells and (ii) the ability to stimulate interferon-alpha (IFN-α
) production by human peripheral blood mononuclear cells. - View Dependent Claims (3, 4, 5, 6)
- S1—
-
2. A method of modulating an immune response in an individual comprising administering to an individual a linear CIC in an amount sufficient to modulate an immune response in said individual, wherein the linear CIC is selected from the group consisting of:
Specification